UROLOGY / RESEARCH PAPER
Kinesin family member 14 (KIF14) induces tumor cell proliferation in muscle invasive bladder cancer (MIBC)
More details
Hide details
1 |
Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine |
CORRESPONDING AUTHOR
Xiang-Jun Xu
Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine
Submission date: 2020-01-29
Final revision date: 2020-04-20
Acceptance date: 2020-04-22
Online publication date: 2021-04-10
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Bladder cancer ranks the first in the morbidity of urogenital malignancies in China. Bladder cancers are pathologically classified into 2 sub-types, including non-muscle invasion bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). MIBC is a highly lethal tumor and targeted therapies showed promising prospect for the treatment of MIBC. Novel therapeutic targets are still badly needed to combat this disease. The kinesin family member 14 (KIF14) is an engaging molecular motor and involved in multiple cellular processes such as cell division. Additionally, KIF14 is highly expressed in multiple tumor tissues and participates in the progression of several cancers such as gastric cancer and hepatocellular carcinoma. However, its possible role in the development of bladder cancer remains unclear.
Material and methods:
Herein, 107 cases of MIBC tissue specimens were collected and detected by immunohistochemistry assays, and we analyzed the relationship between AKIF14 expression and clinical features. Then we used the cell line T24 and 5637 of bladder cancer into the experimental group transfected shKIF14 plasmid.KIF14, additionally, fascinated tumor growth of MIBC in mice.
Results:
We demonstrated the high expression of KIF14 in tumor tissues from patients who underwent MIBC. Furthermore, KIF14 was statistically correlated with clinical feature, such as tumor stage (P = 0.001). Our results further confirmed the impairment of proliferation capacity after KIF14 ablation in vitro and in vivo.
Conclusions:
In summary, we revealed KIF14 could serve as a promising therapeutic target for the treatment of MIBC.